1. Cell Cycle/DNA Damage Autophagy Anti-infection Apoptosis
  2. Topoisomerase Autophagy Mitophagy Bacterial Apoptosis Antibiotic
  3. Etoposide

Etoposide  (Synonyms: 依托泊苷; VP-16; VP-16-213)

目录号: HY-13629 纯度: 99.94%
COA 产品使用指南

Etoposide (VP-16; VP-16-213) 是一种常用的抗肿瘤化疗剂。Etoposide 抑制拓扑异构酶 II (topoisomerase-II),从而抑制 DNA 复制。Etoposide 诱导细胞周期停滞,凋亡 (apoptosis) 和自噬 (autophagy)。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Etoposide Chemical Structure

Etoposide Chemical Structure

CAS No. : 33419-42-0

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥567
In-stock
5 mg ¥150
In-stock
10 mg ¥200
In-stock
50 mg ¥368
In-stock
100 mg ¥515
In-stock
200 mg ¥871
In-stock
500 mg ¥2000
In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Etoposide:

注册 MCE会员完成审核
即刻享有 积分商城 300 专属积分

Top Publications Citing Use of Products

MCE 顾客使用本产品发表的 79 篇科研文献

WB
RT-PCR
IF
Proliferation Assay
Cell Viability Assay

    Etoposide purchased from MCE. Usage Cited in: Oncogene. 2023 Feb 2.  [Abstract]

    Etoposide (VP16; 5 mg/kg; s.c.; every two days for 8 days) strongly suppresses tumor growth in mice.

    Etoposide purchased from MCE. Usage Cited in: J Pharm Pharmacol. 2023 Mar 1;rgad007.  [Abstract]

    Irinotecan (CPT11; 20 μM; 48 h) or Etoposide (VP16; 20 μM; 48 h) induces MDA-MB-231 cells cycle arrest significantly.

    Etoposide purchased from MCE. Usage Cited in: Elife. 2022 May 3;11:e69255.  [Abstract]

    Cell sensitivity to Etoposide (ETO). Cancer cells are treated with etoposide at gradient concentrations for 48 hr.

    Etoposide purchased from MCE. Usage Cited in: Elife. 2022 May 3;11:e69255.  [Abstract]

    BCL6 mRNA expression in Etoposide (ETO)-resistant and -sensitive cells. Cells are treated with Etoposide at their respective 1/2 IC50s for 24 hr.

    Etoposide purchased from MCE. Usage Cited in: Elife. 2022 May 3;11:e69255.  [Abstract]

    Etoposide activated mTOR signaling components in Etoposide-resistant Capan-2 and PANC28 cells. Cells were treated with etoposide at their respective 1/2 IC50s for 6 or 12 hr. A long-term treatment with Etoposide activated mTOR signaling components in ETO-resistant cells. Capan-2 and PANC28 cells are treated with 10 μM Etoposide for 2 or 4 days.

    Etoposide purchased from MCE. Usage Cited in: Elife. 2022 May 3;11:e69255.  [Abstract]

    STAT1 protein and its phosphorylation levels by immunoblotting analysis. Etoposide (ETO)-resistant and -sensitive cells are treated with Etoposide at their respective 1/2 IC50s for indicated time points.

    Etoposide purchased from MCE. Usage Cited in: Elife. 2022 May 3;11:e69255.  [Abstract]

    Etoposide induced BCL6 protein expression in a time-dependent manner. ETO-resistant or -sensitive cells are treated with etoposide at their respective 1/4 IC50s for 2, 4, or 6 days.

    Etoposide purchased from MCE. Usage Cited in: Protein Cell. 2022 Jan;13(1):47-64.  [Abstract]

    FISH of telomeres on metaphase spreads to detect chromosome end-to-end fusions in 6 kb-HeLa treated with VP-16. Control (Scr) or cGAS-depleted cells (gcGAS-1, gcGAS-2) are either harvested immediately following treatment (VP-16, 2 μM, 1 h) or released for 4 h (Release 4 h) during mitosis.

    Etoposide purchased from MCE. Usage Cited in: Cell Death Dis. 2021 Mar 12;12(3):265.  [Abstract]

    Inhibition of PRDX1 increased the sensitivity of HCT116 cells to Etoposide-induced apoptosis: HCT116 cells infected with lentivirus expressing the indicated shRNAs were treated with 50 μM Etoposide for 0-6 h.

    Etoposide purchased from MCE. Usage Cited in: Adv Sci (Weinh). 2020 Sep 28;7(21):2001364.  [Abstract]

    Lnc‐Ip53 attenuated the DNA damage‐ and oxidation stress‐triggered increase of CDKN1A and PUMA. Cells are incubated with 50 µM Etoposide (Eto) for 6 h.

    Etoposide purchased from MCE. Usage Cited in: Adv Sci (Weinh). 2020 Sep 28;7(21):2001364.  [Abstract]

    Lnc‐Ip53 attenuated the DNA damage- and oxidation stress-induced p53 acetylation at K382. Cells are incubated with 50 µM Etoposide (Eto) for 5 h.

    Etoposide purchased from MCE. Usage Cited in: Hepatology. 2020 May;71(5):1660-1677.  [Abstract]

    Exposure to Etoposide (Eto), another DNA-damaging agent, induces PDIA3P1 expression, suggesting that PDIA3P1 may be up-regulated by DNA-damaging agents.

    Etoposide purchased from MCE. Usage Cited in: Theranostics. 2020 Jul 25;10(21):9477-9494.  [Abstract]

    When cells are treated with 20 µM Etoposide or DMSO (vehicle group) for 4 h, western blots (WB) shows elevated expression of γH2AX, a marker of double-strand breaks (DSBs), in the Etoposide group.

    Etoposide purchased from MCE. Usage Cited in: Theranostics. 2020 Jul 25;10(21):9477-9494.  [Abstract]

    When cells are treated with 20 µM Etoposide, an obvious increased green focus of RAD51 is observed in the treated fibroblasts using immunofluorescence (IF) staining.

    Etoposide purchased from MCE. Usage Cited in: Theranostics. 2020 Jul 25;10(21):9477-9494.  [Abstract]

    Fibroblasts and HT-1080 cells are treated with 20 µM Etoposide or DMSO (vehicle group) for 2, 4, 8, 16, 24 and 36 h.

    Etoposide purchased from MCE. Usage Cited in: EMBO Mol Med. 2020 Nov 6;12(11):e12525.  [Abstract]

    Immunoblot of PARP1 cleavage of PeTa cells after 6 days of indicated treatment. Etoposide (10 μM; for 24 h) serves as positive control for apoptosis, and H3 serves as loading control.

    Etoposide purchased from MCE. Usage Cited in: Aging Cell. 2020 Jul;19(7):e13171.  [Abstract]

    RPE p16‐mCherry cells were treated with DMSO, Etoposide (20 μM), H2O2 (200 μM), or serum starved for 24 hr.

    Etoposide purchased from MCE. Usage Cited in: Leuk Lymphoma. 2018 Jan;59(1):162-170.  [Abstract]

    WT1 and caspase-3 protein levels are detected in two primary AML blasts treated with 100 μM Eto for 24 h.

    Etoposide purchased from MCE. Usage Cited in: Cancer Lett. 2017 Nov 1;408:43-54.  [Abstract]

    Western blot analysis of p-p70S6k, p70S6k, p-AKT and AKT after 6 h of treatment with 20 μM RAD001. Levels of p-p70S6k and p-AKT are quantified by densitometric analysis and a corresponding histogram is constructed as relative to p70S6k or AKT and α-tubulin. The lower panel shows a representative Western blot.
    • 生物活性

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy[1].

    IC50 & Target[1]

    Topoisomerase II

     

    体外研究
    (In Vitro)

    Etoposide 能够通过 JNK/ERK 介导的 GSK-3 下游触发的 RIN-m5F 细胞线粒体依赖性信号通路诱导细胞凋亡,从而对胰腺 β 细胞产生细胞毒性[1]
    Etoposide 和抗人 VEGF 显著消除 P1 球形成能力,这是一种与该细胞亚群凋亡相关的作用[2]
    磷酸 Etoposide (0-1 μM;72 小时) 以剂量依赖性方式抑制 HCT116 FBXW+/+、FBXW-/- 和 p53-/-,表现出 IC 50=0.945 μM、0.375 μM,和 1.437 μM[5]
    Etoposide (25 μM;6 小时) 延迟 FBXW7 缺陷细胞中的 p53 恢复。此外,FBXW7-/-细胞中 FBXW7 表达消失[5]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[5]

    Cell Line: HCT116 FBXW+/+, FBXW-/- and p53-/- cells
    Concentration: 0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM
    Incubation Time: 72 hours
    Result: Inhibits HCT116 FBXW+/+p>, FBXW-/- and p53-/- cell growth as a concentration manner.

    Western Blot Analysis[5]

    Cell Line: HCT116 FBXW7+/+ or FBXW7-/- cells
    Concentration: 25 μM
    Incubation Time: 6 hours
    Result: Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7.
    体内研究
    (In Vivo)

    将 Etoposide (50 μM) 和经抗人 VEGF 处理的缺氧细胞静脉注射到免疫缺陷小鼠体内,显示诱导肺集落的能力降低,并且潜伏期较长[2]。Etoposide (10 mg/kg/天,静脉注射) 与 NSC 109724 和 NSC 241240 一起,减少注射了肝母细胞瘤细胞的 NMRI 裸鼠的肿瘤体积[3]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    分子量

    588.56

    Formula

    C29H32O13

    CAS 号
    性状

    固体

    颜色

    White to off-white

    中文名称

    依托泊苷;臼乙叉苷;足叶乙甙

    结构分类
    初始来源
    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    溶解性数据
    In Vitro: 

    DMSO 中的溶解度 : ≥ 39 mg/mL (66.26 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

    * "≥" means soluble, but saturation unknown.

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 1.6991 mL 8.4953 mL 16.9906 mL
    5 mM 0.3398 mL 1.6991 mL 3.3981 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    In Vivo:

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (4.25 mM); 澄清溶液

      此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

      1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

      生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
    • 方案 二

      请依序添加每种溶剂: 10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (4.25 mM); 澄清溶液

      此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液,此方案实验周期在半个月以上的动物实验酌情使用。

      1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

    动物溶解方案计算器
    请输入动物实验的基本信息:

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    由于实验过程有损耗,建议您多配一只动物的量
    请输入您的动物体内配方组成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
    连续给药周期超过半月以上,请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
    纯度 & 产品资料

    纯度: 99.94%

    参考文献

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.6991 mL 8.4953 mL 16.9906 mL 42.4766 mL
    5 mM 0.3398 mL 1.6991 mL 3.3981 mL 8.4953 mL
    10 mM 0.1699 mL 0.8495 mL 1.6991 mL 4.2477 mL
    15 mM 0.1133 mL 0.5664 mL 1.1327 mL 2.8318 mL
    20 mM 0.0850 mL 0.4248 mL 0.8495 mL 2.1238 mL
    25 mM 0.0680 mL 0.3398 mL 0.6796 mL 1.6991 mL
    30 mM 0.0566 mL 0.2832 mL 0.5664 mL 1.4159 mL
    40 mM 0.0425 mL 0.2124 mL 0.4248 mL 1.0619 mL
    50 mM 0.0340 mL 0.1699 mL 0.3398 mL 0.8495 mL
    60 mM 0.0283 mL 0.1416 mL 0.2832 mL 0.7079 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    Etoposide
    目录号:
    HY-13629
    需求量: